CRISPR Core Partner Events

Some of the many benefits to joining our exclusive CRISPR Core Partnership Program are the CRISPR Core Directors Meetings, held in both North America and Europe. These annual events bring our Core partners together to collaborate with the global scientific community and further develop the field of gene editing.

 2017 CRISPR Core Directors Meeting – North America

Monterey, CA – September 19-20, 2017

In late September, the 7th North American CRISPR Core Directors meeting was held in Monterey, CA, hosting nearly 30 core directors from 24 different core facilities across the country. The two-day event saw presentations from guest speakers, core partners and our internal colleagues on topics ranging from experimental design and tips, screening approaches, animal model generation, and Hirschsprung disease to the very latest developments in the CRISPR field. Discussion sessions provided insight into the challenges customers face in their day-to-day activities, and how we can help them overcome and solve these challenges with greater support, expertise and product development. This meeting was a true collaboration with the global scientific community to further develop the field of gene editing. The event closed by welcoming three new partners into the program, bringing our total number of global CRISPR Core Partners to 61.

This networking event is one of the key benefits of the CRISPR Core Partnership Program. The Core partnership program provides leading scientists at core facilities with early access to our innovative CRISPR reagents, collaboration with our R&D team, personalized technical support and networking events with leaders in the gene editing field. By empowering core facility researchers with greater access to these technologies and supporting resources, breakthrough discoveries can be made quickly, confidently and accurately.

Agenda Details (PDF)

 2017 CRISPR Core Directors Meeting – Europe

Cambridge, England - June 19-20, 2017

In June of 2017, the 3rd Annual European CRISPR Core Director Meeting was held in Cambridge, England. The event gathered key opinion leaders in Academia and Pharma in the Genome Editing field, representing 30 Core Facilities from 12 different countries across Europe and the Middle East. The two-day event included presentations from guest speakers and Merck colleagues on topics ranging from experimental design, screening approaches, and animal model generation to the very latest developments in the CRISPR field, including a keynote presentation on CRISPR Targeting in Organoids.

Discussion sessions provided insight into the challenges our customers face in their day-to-day activities, and how Merck can help them overcome and solve these challenges with greater support, expertise and product development. This meeting was a true collaboration with the global scientific community to further develop the field of gene editing.

Agenda Details (PDF)

 2016 CRISPR Core Directors Meeting – North America

Hull, MA – September 20-21, 2016

In September of 2016, Sigma-Aldrich held their biannual core facility director networking event in Hull, MA. The event brought together 41 attendees to discuss transgenic animal creation, pooled and arrayed screening, donor design and troubleshooting, synthetic gRNA and RNP complexes, and dCas9 epigenetic activators.The two-day event featured directed seminars, guest lectures, and discussion forums on a wide variety of CRISPR topics. Attendees collaborated with technical experts, other core directors, and key opinion leaders in the genome editing field.

Agenda Details (PDF)


 2016 CRISPR Core Directors Meeting – Europe

Copenhagen, Denmark June 13-14, 2016

In June of 2016, the European CRISPR Core Director’s meeting was held in Copenhagen, Denmark. The event gathered key opinion leaders in the Genome Editing field representing 28 Core Facilities from 12 different countries across Europe. The two-day event saw presentations from guest speakers and internal colleagues on a variety of topics ranging from experimental design, screening approaches, animal model generation to the very latest developments in the CRISPR field. Discussion sessions provided insight into challenges researchers face in their day-to-day activities and how we can help overcome these with greater support, expertise and product development.

Agenda Details (PDF)